For this purpose, we utilized Dasatinib that is a multi-targeted orally administered inhibitor of RTKs and Src family of tyrosine kinases [17] that is FDA approved treatment for chronic myelogenous leukemia (CML). This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.